Skip to navigation Skip to content

Clinical Trials: Transcranial Direct Current Stimulation Studies

Share

Details
Type of MS: PPMS|PRMS|RRMS|SPMS
Treatment mode of action: See Below
Number of Subjects: 200
Medication: Transcranial Direct Current Stimulation
Location: New York
Institutions: Institution: NYU Langone Health's Multiple Sclerosis Comprehensive Care Center (MSCCC) Contact Information
See Below

Funding:

See Below

Description

Researchers at New York University are recruiting people with MS for three studies involving transcranial direct current stimulation (tDCS, which involves low electrical current delivered via electrodes).

Clinical Trial: A Pilot Trial of Remotely-Supervised Transcranial Direct Current Stimulation (RS-tDCS) to Enhance Motor Learning in Progressive Multiple Sclerosis (MS)
Type of MS: Progressive Multiple Sclerosis (SPMS or PPMS)
Treatment mode of action: To improve finger use and hand strength
Number of Subjects: 80
Medication: Transcranial Direct Current Stimulation (RS-tDCS)
Address: NYU Ambulatory Care Center: 222 East 41st Street, 10th floor, New York, NY, 10017;
or at NYU’s satellite location in Huntington, NY: 789 Park Ave, Huntington, NY 11743.
Contact Name: Matt Lustberg
Phone: (929) 455-5090
Email: matthew.lustberg@nyulangone.org 
Funding: Department of Defense
Brief Description: Participants with progressive MS complete hand training exercises that are designed to improve finger use and hand strength at home. Participants are randomly assigned to receive either active or placebo transcranial direct current stimulation (tDCS, which involves low electrical current delivered via electrodes) while completing their hand exercises each day. This study is completed at home, through the use of videoconferencing with a study techician using a computer, provided by the MS Center. Sessions occur daily, Monday-Friday, for four weeks for a total of 20 sessions. Each session lasts 30 minutes. If assigned to placebo condition, additional 10 sessions of active tDCS will be offered without cost to participant at the study end.
 
Clinical Trial: Neuroimaging with Transcranial Direct Current Stimulation (tDCS)                  
Type of MS: All types
Treatment mode of action: Neuroimaging with tDCS
Number of Subjects: 60 (40 with MS)
Medication: Transcranial Direct Current Stimulation
Address: NYU Ambulatory Care Center: 222 East 41st Street, 10th floor, New York, NY, 10017;
Contact Name: Kai Sherman
Phone: 929 455 5125
Email: Kai.Sherman@nyulangone.org
Funding: Unfunded
Brief Description: The objective of this trial is to measure the change in nervous sytem activities while receiving transcranial direct current stimulation  (tDCS, which involves low electrical current delivered via electrodes).  Participants will receive tDCS during an MRI neuroimaging session. Participants will complete self-report measures and a brief cognitive assessment, and then undergo an hour-long stand-alone MRI scan with approximately 15 minutes of tDCS administered during the scan.

Clinical Trial:Transcranial direct current stimulation (tDCS) for the Management of Multiple Sclerosis Related Fatigue 
Type of MS: SPMS, RRMS, PPMS
Treatment mode of action: To reduce fatigue
Number of Subjects: 120
Medication: tDCS
Address: NYU Ambulatory Care Center: 222 East 41st Street, 10th floor, New York, NY, 10017;
or at NYU’s satellite location in Huntington, NY: 789 Park Ave, Huntington, NY 11743.
Contact Name: Matthew Lustberg
Phone: (929) 455-5090
Email: matthew.lustberg@nyulangone.org
Funding:NMSS
Brief Description: To test the treatment benefit of transcranial direct current stimulation (tDCS) to reduce MS-related fatigue and associated symptoms. Participants will complete 30 daily (20 minute) cognitive training sessions from home over six weeks, and will be randomly assigned to receive either active or sham (placebo) tDCS during the training. At the first visit, scheduled at our clinic, participants will complete initial cognitive testing and questionnaires and be trained on the study-provided computer and tDCS device to take home for the study period. Each daily session will be supervised by a live tDCS technician via videoconference. At the end of the 6 weeks, participants will return to the clinic for a follow-up assessment. If assigned to sham (placebo) condition, an additional 10 sessions of active tDCS will be offered without cost to participant at the study end. Compensation will be provided.

Share


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.